<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074384</url>
  </required_header>
  <id_info>
    <org_study_id>04356-14-A</org_study_id>
    <nct_id>NCT02074384</nct_id>
  </id_info>
  <brief_title>Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)</brief_title>
  <official_title>Understanding Patient and Provider Glucose Reporting Preferences in Type 1 Diabetes: Cloud Based Ambulatory Glucose Profile (AGP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International Diabetes Center (IDC) proposes a preference and usability study of glucose data
      acquisition and reporting, evaluating streamlined standardized cloud-based glucose reporting
      including work flow as well as patient and clinician preference at Type 1 Diabetes (T1D)
      Exchange sites to enhance standard Ambulatory Glucose Profile (AGP) reporting. This phase 2
      project assesses the efficacy of standardized glucose data report generation and preferred
      report presentation format; both are necessary to increase use of continuous glucose
      monitoring (CGM) data to improve care processes and outcomes for Type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient participation in diabetes treatment has relied upon episodic self-monitoring of blood
      glucose (SMBG). SMBG assists patients and clinicians with adjustments of insulin,
      identification of hypoglycemia, nutritional intake and activity in order to optimize diabetes
      control. SMBG however is subject to bias dependent upon the testing frequency and timing. In
      contrast, continuous glucose monitoring (CGM) systems capture continuous 24-hour glucose data
      uninterrupted and unbiased. It provides valuable information about daily/nightly alterations
      in glucose patterns. Unfortunately SMBG, CGM and insulin pump devices have proprietary
      software with unique data standards, acquisition methods, reports, and graphic displays.
      These differences make evaluation and comparison of SMBG or CGM data difficult for clinicians
      and patients. IDC created an Ambulatory Glucose Profile (AGP) report to reduce challenges of
      device specific reports through a standardized report which is produced from any device with
      streamlined graphic displays of glucose trends.

      The phase 1 project (2012), gathered expert stakeholders (clinical, research, industry,
      patients) who validated data standards and recommended changes to the CGM-AGP reports. These
      changes are now integrated into a secure cloud-based infrastructure for AGP reporting.

      Phase 2 of this project is a usability and preference study of glucose reporting systems. It
      will include an in depth study of 6 T1D Ex clinical sites. The T1D Exchange Clinic Network
      was formed to support the development of a large registry of adults and children with type 1
      diabetes for the purpose of conducting multiple studies proposed by T1D Exchange
      investigators, and other researchers, patients, and companies.

      The 6 sites will be selected for an in-depth study utilizing middleware data collection
      services (Diasend or SweetSpot) to facilitate efficient collection of data from diverse
      devices. These middleware solutions integrate with the captÅ«rAGP system to automatically
      produce an AGP report. These sites will test the feasibility of AGP cloud reporting while
      collecting patient and clinician opinions on report preference. All 6 sites participating in
      phase 2 will collect patient and clinician preference measures. Two study sites will undergo
      time in motion (TIM) measurement and workflow mapping of current process. This TIM sub-study
      includes workflow mapping of current and cloud-based processes utilizing Toyota Lean (Kaizen)
      methodology. Sites 3 - 6 will receive enhanced designs through the adaptive trial method with
      learnings applied from sites 1 and 2.

      A key deliverable of this study is patient and clinician insight into their utilization of
      CGM reporting technologies. Recognizing that adoption of technology is often stymied by time
      constraints, report reliability and ease of interpretation, these variables will be examined.
      The goal of phase 2 is to analyze the viability of standard reporting and to evaluate
      preference (patient and clinicians) for and perceived value of different types of glucose
      pattern reports (AGP vs. device) including clinical practice time saved.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports</measure>
    <time_frame>At the end of the two week SMBG or CGM period</time_frame>
    <description>Patients will use either SMBG or CGM for a two week period following their screening visit. At the end of the two week period they will return to the study site to download their device and have an AGP report printed. They will then complete a preference and utility survey.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Continuous Glucose Monitoring</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will wear Continuous Glucose Monitoring for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self Monitoring Blood Glucose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will self test for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinicians</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clinicians completing study visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitor</intervention_name>
    <description>CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.</description>
    <arm_group_label>Continuous Glucose Monitoring</arm_group_label>
    <other_name>Dexcom G4 professional version Continuous Glucose Monitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Self Monitoring Blood Glucose</intervention_name>
    <description>Participants will use their own SMBG device.</description>
    <arm_group_label>Self Monitoring Blood Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinician</intervention_name>
    <description>Survey of clinicians after study visits</description>
    <arm_group_label>Clinicians</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetics

        Exclusion Criteria:

          -  Less than the age of 7

          -  Non-English Speaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Bergenstal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Mulllen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park Nicollet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eda Cengiz</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry Deeb</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Diabetes Center, PLLC</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>November 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2016</results_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Glucose Monitoring</title>
          <description>Participants will wear Continuous Glucose Monitoring for two weeks.
Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.</description>
        </group>
        <group group_id="P2">
          <title>Self Monitoring Blood Glucose</title>
          <description>Participants will self test for two weeks.
Self Monitoring Blood Glucose: Participants will use their own SMBG device.</description>
        </group>
        <group group_id="P3">
          <title>Clinicians</title>
          <description>Clinicians completing study AGP visits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuous Glucose Monitoring</title>
          <description>Participants will wear Continuous Glucose Monitoring for two weeks.
Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.</description>
        </group>
        <group group_id="B2">
          <title>Self Monitoring Blood Glucose</title>
          <description>Participants will self test for two weeks.
Self Monitoring Blood Glucose: Participants will use their own SMBG device.</description>
        </group>
        <group group_id="B3">
          <title>Clinicians</title>
          <description>Clinicians completing the study visits.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" spread="14.5"/>
                    <measurement group_id="B2" value="28.8" spread="18.7"/>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="26.4" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports</title>
        <description>Patients will use either SMBG or CGM for a two week period following their screening visit. At the end of the two week period they will return to the study site to download their device and have an AGP report printed. They will then complete a preference and utility survey.</description>
        <time_frame>At the end of the two week SMBG or CGM period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Participants will wear Continuous Glucose Monitoring for two weeks.
Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.</description>
          </group>
          <group group_id="O2">
            <title>Self Monitoring Blood Glucose</title>
            <description>Participants will self test for two weeks.
Self Monitoring Blood Glucose: Participants will use their own SMBG device.</description>
          </group>
          <group group_id="O3">
            <title>Clinicians</title>
            <description>Clinicians completing the study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports</title>
          <description>Patients will use either SMBG or CGM for a two week period following their screening visit. At the end of the two week period they will return to the study site to download their device and have an AGP report printed. They will then complete a preference and utility survey.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuous Glucose Monitoring</title>
          <description>Participants will wear Continuous Glucose Monitoring for two weeks.
Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.</description>
        </group>
        <group group_id="E2">
          <title>Self Monitoring Blood Glucose</title>
          <description>Participants will self test for two weeks.
Self Monitoring Blood Glucose: Participants will use their own SMBG device.</description>
        </group>
        <group group_id="E3">
          <title>Clinicians</title>
          <description>Clinicians completing study visits.
Clinician: Survey of clinicians after study visits</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a survey of patient and clinician preference and as such is subject to traditional survey biases (social desirability, hawthorne effect, etc.).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Deborah Mullen</name_or_title>
      <organization>Park Nicollet Institute</organization>
      <phone>952-993-2070</phone>
      <email>deborah.mullen@parknicollet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

